FDA OKs vitamin C trial for cancer

Jan 12, 2007

Federal approval of a clinical trial on intravenous vitamin C as a cancer treatment lends credence to alternative cancer care, U.S. researchers said.

Cancer Treatment Centers of America said it won Food and Drug Administration approval to begin the trial, a move the Illinois-based hospital group said adds credibility to its research into alternative methods for cancer medical care, the Chicago Tribune said Thursday. It is the first FDA-approved trial for CTCA.

Just a few patients will be eligible, said Christopher Lis, the firm's vice president of research and development.

"Only patients who have exhausted all other conventional treatment options are eligible to receive the therapy," Lis said.

The first phase will be to determine the optimal dose for the patients and to learn whether the treatment is safe and can be tolerated, Lis said. Additional studies over several years would be needed to demonstrate whether it is effective.

Earlier studies conducted with vitamin C supplements administered orally did not to demonstrate a clinical benefit to cancer patients.

Cancer Treatment Centers, with facilities in Illinois, Pennsylvania and Oklahoma, provides traditional and alternative treatment for cancer patients.

Copyright 2007 by United Press International

Explore further: New chemical technology boosts potency of targeted cancer therapy

Related Stories

Gold nanoparticles for targeted cancer treatment

Mar 26, 2015

The use of tiny drug-loaded nanocarriers for the safe, targeted delivery of drugs to designated parts of the body has received much press in recent years. Human trials of nanocarriers targeting pancreatic ...

Recommended for you

Using healthy skin to identify cancer's origins

17 hours ago

Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The findings illuminate the first steps cells take towards becoming a cancer and de ...

Gender differences in receipt of end-of-life care

17 hours ago

(HealthDay)—There are gender differences in receipt of end-of-life (EoL) care among terminally ill cancer patients, with male patients more likely to receive intensive care unit (ICU) care, according to ...

Scientists unveil prostate cancer's 'Rosetta Stone'

19 hours ago

Almost 90 per cent of men with advanced prostate cancer carry genetic mutations in their tumours that could be targeted by either existing or new cancer drugs, a landmark new study reveals.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.